Results 151 to 160 of about 2,423,946 (178)

Anti-PLA2R Antibodies Measured by ELISA Predict Long-Term Outcome in a Prevalent Population of Patients With Idiopathic Membranous Nephropathy

Kidney International, 2013
Antibodies to the phospholipase A2 receptor 1 (PLA2R1) have been reported in 70% of cases of idiopathic membranous nephropathy (IMN). The genetic susceptibility of IMN has been accounted for by HLA DQA1 and PLA2R1 genes.
Milind Nikam, Stephen A. Roberts, Paul E Brenchley   +2 more
exaly   +2 more sources

Pregnancy in a Patient With Primary Membranous Nephropathy and Circulating Anti-PLA2R Antibodies: A Case Report [PDF]

American Journal of Kidney Diseases, 2016
There is little information about pregnancy outcomes in patients with active membranous nephropathy (MN), especially those with circulating autoantibodies to M-type phospholipase A₂receptor (PLA₂R), the major autoantigen in primary MN. We present what we believe to be the first known case of successful pregnancy in a 39-year-old woman with PLA₂R ...
Ramon G Bonegio, David J Salant, Joel M Henderson   +2 more
exaly   +3 more sources

Clinical Outcomes of Immunosuppressive Therapy in Patients With Seronegative Anti-PLA2R Antibodies and PLA2R-Related Membranous Nephropathy

Clinical and Experimental Nephrology
Abstract Background Idiopathic membranous nephropathy (IMN) is an autoimmune disease characterized by anti-PLA2R antibodies, which are linked to disease activity, prognosis, and relapse. While guidelines recommend immunosuppressive treatment for high antibody levels, the impact on PLA2R-negative patients remains unclear.
Qijun Wan, Zhihang Su
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Anti-PLA2R antibodies promote endothelial pyroptosis and a procoagulant phenotype through FcγRI signaling

Nephrology Dialysis Transplantation
ABSTRACT Background and hypothesis Thromboembolism is a serious complication of nephrotic syndrome and occurs disproportionately in membranous nephropathy (MN). Whether anti-phospholipase A2 receptor (PLA2R) antibodies and complement activation directly promote endothelial dysfunction and ...
Cai-xia Lin, Qi-qi Ma, Hui Lu, Ping Wang, Huang Kuang, Miao Wang, Yu Xiao, Dong-mei Xu, Gao-si Xu, Ming-hui Zhao, Zhao Cui   +10 more
openaire   +2 more sources

[Anti-NEP and anti-PLA2R antibodies in membranous nephropathy: an update].

Revue medicale de Bruxelles, 2015
Membranous nephropathy (MN) is the most common cause for nephrotic syndrome in adults and occurs as an idiopathic (primary) or secondary disease. Since the early 2000's, substantial advances have been made in the understanding of the molecular bases of MN. The neutral endopeptidase (NEP) and the receptor for secretory phospholipase A2 (PLA2R) have been
A A, Pozdzik, H, Debiec, , I Brochériou, C, Husson, S, Rorive, N, Broeders, A, Le Moine, P, Ronco, J, Nortier   +8 more
openaire   +1 more source

Anti-PLA2R antibody levels are associated with thromboembolism risk in individuals with membranous nephropathy and hypoalbuminemia

Journal of Nephrology
Abstract Background Studies to evaluate markers of thrombotic risk in individuals with high-risk membranous nephropathy (MN) are needed. We hypothesized that high anti-phospholipase A2 receptor (PLA2R) titers at the time of severe hypoalbuminemia, reflecting ongoing immunologic disease activity,
Ayman Al Jurdi, Christopher El Mouhayyar, Karim Yatim, Orhan Efe, Saif A Muhsin, Leonardo V Riella, Reza Zonozi, Karen Laliberte, John L Niles, Anushya Jeyabalan   +9 more
openaire   +2 more sources

Comparison of measurements of anti-PLA2R antibodies in Japanese patients with membranous nephropathy using in-house and commercial ELISA

Clinical and Experimental Nephrology, 2019
The prevalence of antibodies against M-type anti-phospholipase A2 receptor (PLA2R) was reported to be ~ 70-80% in early studies on idiopathic membranous nephropathy (iMN) cohorts from Western countries, China, and Korea, and ~ 50% in recent studies on two Japanese iMN cohorts.We developed an in-house enzyme-linked immunosorbent assay (ELISA) for the ...
Hajime, Kaga, Atsushi, Komatsuda, Soh, Yamamoto, Tadashi, Kikuchi, Mika, Kamata, Akiko, Sato, Masafumi, Odaka, Shin-Ichi, Yokota, Naoto, Takahashi, Hideki, Wakui   +9 more
openaire   +2 more sources

Prevalence of Anti-PLA2R Antibodies in Biopsy Proven Membranous Nephropathy in Egyptian Patients

QJM: An International Journal of Medicine
Abstract Background Membranous nephropathy (MN) is among the most common causes of the nephrotic syndrome in nondiabetic adults, accounting for approximately 20 to 30 percent of cases of nephrotic syndrome in White adults.
Magdy Saed El-Sharkawy, Ahmed Abd-Elmoniem Emara, Reem Mohsen El-Sharabasy, Mohamed Mostafa Mostafa Megahed   +3 more
openaire   +1 more source

ANTI-PLA2R ANTIBODY AND PRIMARY MEMBRANOUS NEPHROPATHY: A LITERATURE REVIEW

International Journal of Health Science, 2023
Kívia da Silva Joia, Raphaella Bogado de Bem, Ana Carolina Alves da Conceição, Karina Mourão Costa, Alexandra da Silva Barros, Thaynara Alves de Souza Maciel, Ana Carolina do Amaral Santos de Carvalho Rocha, Raquel Alencar Sampaio Ferraz, Patrick de Abreu Cunha Lopes, Marco Antônio Netto Armando Rangel, Ricardo José de Farias Neto   +10 more
openaire   +1 more source

Serum Anti-PLA2R Antibody Predicts Treatment Outcome in Idiopathic Membranous Nephropathy.

American journal of nephrology, 2017
M-type phospholipase A2 receptor (PLA2R) has been identified as the major target antigen in idiopathic membranous nephropathy (IMN). However, the role of glomerular PLA2R (gPLA2R) and the associations of serum anti-PLA2R antibody (sPLA2R-Ab) titre with diagnosis, treatment and prognosis in IMN need to be further investigated.We screened 148 consecutive
Shi-Yao, Wei, Yu-Xiao, Wang, Jian-Si, Li, Shi-Lei, Zhao, Tian-Tian, Diao, Yu, Wang, Chang, Wang, Ying, Qin, Yang, Cao, Qiuju, Wei, Bing, Li   +10 more
openaire   +1 more source